Navigation Links
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial

are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the FDG-PET clinical


-- failure to obtain sufficient data from enrolled patients that can be

used to evaluate VIA-2291, thereby impairing the validity or

statistical significance of our clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291 on

expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiovascular clinical

trials using histological examinations, measurement of biomarkers,

medical imaging and atherosclerotic plaque bioassays;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product


-- our ability to form and maintain collaborative relationships to develop

and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under Item IA "Risk Factors" in our Annual

Report on Form 10-K for the fiscal year ended December 31, 2007 on file

with the SEC.

All forward-looking statements attributable to us or persons acting

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
(Date:10/25/2014)... 24, 2014 Best Practices designed the ... with a forum for sharing insights about the ... a mechanism for creating and sharing solutions through ... findings from the Medical Affairs Consortium survey. ... for the first roundtable of the 2014-2015 Medical ...
(Date:10/22/2014)... SANTA CLARA, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced the introduction of the cQUB™-1 (cQuest Ultrasound ... cQUB white-label ultrasound systems designed and manufactured by Cephasonics ... brand name and model number. Cephasonics will be showcasing ... 2014 being held this week in Chongqing, ...
(Date:10/22/2014)... 2014 Investor-Edge has initiated coverage ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ), ... these five companies can be accessed at: ... NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow ...
Breaking Medicine Technology:Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
... SAN DIEGO, Feb. 16, 2012  Cardium Therapeutics (NYSE Amex: ... completed the previously announced sale of 17,857,143 shares of ... gross proceeds of approximately $5.0 million, before deducting placement ... and accredited investors participating in the offering purchased the ...
... Bionovo, Inc. (OTC Link Platform: BNVI.PK) a pharmaceutical company ... effective treatments for women,s health and cancer, announced today ... February 21, 2012 at 1:30 PM PST to discuss ... 31, 2011. (Logo: ) ...
Cached Medicine Technology:Cardium Announces Closing of $5.0 Million Equity Financing 2Cardium Announces Closing of $5.0 Million Equity Financing 3
(Date:10/25/2014)... Oct. 25, 2014 (HealthDay News) -- Arriving home safe and ... To that end, be sure that costumes and goody ... Dr. Sampson Davis, an emergency medicine doctor at Meadowlands Hospital ... carry a flashlight, and costumes should be flame-resistant, Davis said. ... plan to use makeup, test it on a small area ...
(Date:10/25/2014)... 25, 2014 TASC (Total Administrative ... other benefits account management services, announces the release ... save on taxes, reduce administrative workload, and lessen ... savings and the efficient handling of complex, time-sensitive, ... that best meets their goals and objectives. The ...
(Date:10/25/2014)... Oshkosh, Wisconsin (PRWEB) October 25, 2014 ... looking for a great selection at affordable prices. Bob ... Civic Center Huntington Center and Nationwide Arena are going ... quickly. , Click Here to browse the ... Bullet Band at , The famous singer is ...
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... Steven Reinberg HealthDay Reporter ... that causes common cold sores -- herpes simplex -- might ... researchers suggest. In fact, being a carrier of certain ... disease, the researchers found. "The identification of a ... is a breakthrough," said lead researcher Dr. Hugo Lovheim, an ...
Breaking Medicine News(10 mins):Health News:Tips for Safe Trick-or-Treating 2Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3
... during pregnancy can reduce the incidence of pregnancy ... published by American Journal of Obstetrics and Gynecology. ... elevated blood pressure and proteinuria (high levels of ... hands and legs is usually seen. If left ...
... National Institute of Dental and Craniofacial Research, Marquette ... Center for Disease Control, and the National Center ... towards achieving the "Healthy People 2010 Oral Health ... combined meeting of the American Association for Dental ...
... on the sale of the soft drinks stating that it ... round the corner, there is// every possibility of children opting ... drinks has bad affects on the health of schoolchildren, specially ... the sale of these aerated drinks in government-run schools," Ghanshyam ...
... in reducing the bad cholesterol. For example food like oat ... that by combining these food substances one can get the ... they are at a higher risk of getting a heart ... (LDL) as effectively as a commonly prescribed medication. ...
... Smithkline (Britain's biggest drug manufacturer) is being registered for ... vaccine would be marketed for commercial use, by the ... similar vaccine produced by the US pharmaceuticals giant Merck ... It has been proposed to register Cervarix in the ...
... been taken into police custody after a patient died ... named, was hauled up for questioning// after a grandfather ... ,60-year-old Alan Dunn, a resident of Ferryhill, County ... he had apparently stabbed himself was removed from his ...
Cached Medicine News:Health News:Choose Foods That Keep Bad Cholesterol at Bay 2
... Mini Step™ device components are supplied sterile. , ... System is supplied sterile in 2/3, 5, 7/8, ... configurations and combinations. They are used in conjunction ... the Step™ radially Expandable Sleeve. The 5, 7/8, ...
... contains an internal seal to prevent gas leakage ... of pneumoperitoneum. The 5 mm PLUS system includes ... mm - 12 mm as appropriate and is ... of the trocar to allow insertion of smaller ...
VERSAPORT™ Plus RT Single Use Obturators for use with VERSAPORT™ RT Reusable Cannulae....
... SPRING-GRIP™ single use nonconductive anchoring devices are ... mm and 12 mm sizes for use ... mm, 5 mm-10 mm, 5 mm-11 mm, ... sizes for use with the VERSAPORT™, SURGISPIKE™, ...
Medicine Products: